Suppr超能文献

甘油三酯葡萄糖-体重指数在识别非肥胖受试者的非酒精性脂肪性肝病方面是有效的。

Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects.

作者信息

Zhang Shujun, Du Tingting, Li Mengni, Jia Jing, Lu Huiming, Lin Xuan, Yu Xuefeng

机构信息

Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology Department of Health Examination Department of Endocrinology, Wuhan Iron and Steel Company (WISCO) General Hospital, Wuhan, Hubei Province, China.

出版信息

Medicine (Baltimore). 2017 Jun;96(22):e7041. doi: 10.1097/MD.0000000000007041.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is highly correlated with obesity; however, it is not uncommon among nonobese individuals. Triglyceride (TG) and glucose index combined with body mass index (TyG-BMI) has been proposed as a favorable marker of insulin resistance. We sought to investigate the effectiveness of TyG-BMI in identifying NAFLD in nonobese subjects.We conducted a cross-sectional study in a nonobese (BMI <25.0 kg/m) Chinese population (N = 6809) of adults who underwent health examinations, including abdominal ultrasonography.The prevalence of ultrasonography-detected NAFLD was 23.9% in nonobese subjects. After adjusting for potential confounders, every 1-standard deviation increase in TyG-BMI had an odds ratio (OR) of 3.4 [95% confidence interval (95% CI), 3.0-3.9] for NAFLD. Compared with the lowest quartile of TyG-BMI, multivariable-adjusted ORs were 2.4 (1.6-3.6), 6.4 (4.2-9.7), and 15.3 (9.8-23.9) for those in the second, third, and fourth quartile, respectively. According to the receiver operating characteristic curve analysis, TyG-BMI was effective in diagnosing patients with NAFLD with an area under the curve of 0.835 (95% CI, 0.824-0.845). In comparison, TyG-BMI was superior to its components, including TyG, BMI, TG, and fasting plasma glucose, for identifying nonobese subjects at risk for NAFLD.In this study, the prevalence of NAFLD was over one-fifth in the nonobese population. TyG-BMI was an effective marker to detect NAFLD in nonobese subjects.

摘要

非酒精性脂肪性肝病(NAFLD)是一种越来越常见的疾病,与肥胖高度相关;然而,在非肥胖个体中也并不罕见。甘油三酯(TG)和血糖指数与体重指数相结合(TyG-BMI)已被提议作为胰岛素抵抗的一个良好标志物。我们试图研究TyG-BMI在识别非肥胖受试者中的NAFLD方面的有效性。我们对6809名接受健康检查(包括腹部超声检查)的非肥胖(BMI<25.0 kg/m²)中国成年人群进行了一项横断面研究。在非肥胖受试者中,超声检测到的NAFLD患病率为23.9%。在调整潜在混杂因素后,TyG-BMI每增加1个标准差,患NAFLD的比值比(OR)为3.4[95%置信区间(95%CI),3.0-3.9]。与TyG-BMI最低四分位数相比,第二、第三和第四四分位数人群的多变量调整OR分别为2.4(1.6-3.6)、6.4(4.2-9.7)和15.3(9.8-23.9)。根据受试者工作特征曲线分析,TyG-BMI在诊断NAFLD患者方面有效,曲线下面积为0.835(95%CI,0.824-0.845)。相比之下,在识别有NAFLD风险的非肥胖受试者方面,TyG-BMI优于其组成部分,包括TyG、BMI、TG和空腹血糖。在本研究中,非肥胖人群中NAFLD的患病率超过五分之一。TyG-BMI是检测非肥胖受试者中NAFLD的有效标志物。

相似文献

6
[Triglyceride-glucose index in non-obese individuals: its association with and predictive value for non-alcoholic fatty liver disease].
Nan Fang Yi Ke Da Xue Xue Bao. 2024 Jul 20;44(7):1266-1271. doi: 10.12122/j.issn.1673-4254.2024.07.06.
9
The Triglyceride and Glucose Index Is a Predictor of Incident Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study.
Can J Gastroenterol Hepatol. 2019 Oct 7;2019:5121574. doi: 10.1155/2019/5121574. eCollection 2019.

引用本文的文献

2
Research status of triglyceride glucose-body mass index (TyG-BMI index).
Front Cardiovasc Med. 2025 Jul 18;12:1597112. doi: 10.3389/fcvm.2025.1597112. eCollection 2025.
3
Predictive value of triglyceride glucose index in non-obese non-alcoholic fatty liver disease.
BMJ Open. 2025 Apr 8;15(4):e083686. doi: 10.1136/bmjopen-2023-083686.
4
The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD.
Can J Gastroenterol Hepatol. 2025 Mar 13;2025:5871321. doi: 10.1155/cjgh/5871321. eCollection 2025.
5
Association between TyG-related parameters and NAFLD risk in Japanese non-obese population.
Sci Rep. 2025 Feb 28;15(1):7119. doi: 10.1038/s41598-025-88478-3.
6
Value of triglyceride glucose-body mass index in predicting nonalcoholic fatty liver disease in individuals with type 2 diabetes mellitus.
Front Endocrinol (Lausanne). 2025 Jan 20;15:1425024. doi: 10.3389/fendo.2024.1425024. eCollection 2024.

本文引用的文献

1
Nonobese Fatty Liver Disease.
Clin Gastroenterol Hepatol. 2017 Apr;15(4):474-485. doi: 10.1016/j.cgh.2016.08.028. Epub 2016 Aug 28.
2
Lipid phenotypes in patients with nonalcoholic fatty liver disease.
Metabolism. 2016 Sep;65(9):1391-8. doi: 10.1016/j.metabol.2016.06.006. Epub 2016 Jun 25.
5
Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk.
Cardiovasc Diabetol. 2015 Oct 29;14:144. doi: 10.1186/s12933-015-0306-0.
6
Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy.
Am J Gastroenterol. 2015 Sep;110(9):1306-14; quiz 1315. doi: 10.1038/ajg.2015.235. Epub 2015 Jul 28.
8
Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.
Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22. doi: 10.1111/apt.12963. Epub 2014 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验